Clinical Trials Browser

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Carcinoma, Transitional Cell, Neoplasms

Carcinoma, Transitional Cell

Carcinoma, Transitional Cell

Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Carcinoma, Transitional Cell

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

Carcinoma, Transitional Cell, Urogenital Neoplasms

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Carcinoma, Transitional Cell, Myeloproliferative Disorders, Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urogenital Neoplasms, Urologic Neoplasms, Renal Insufficiency

Carcinoma, Transitional Cell

Carcinoma, Transitional Cell, Urologic Neoplasms

Carcinoma, Transitional Cell

Clinical Trials

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

OHAI-NMIBC-01

PRESERVE3

LIVIGNO-3

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

AUREA

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

INDUCOMAIN

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

VINGEM

CVH-CT02

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma

JASINT1

Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer

2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC